Celltrion and Celltrion Health Placement
Temasek aims to raise around US$450m+ via selling 1.7% of Celltrion and Celltrion Healthcare each.There have been two prior selldowns by Temasek in 2018 and 2020 which we covered in:
Celltrion & Celltrion Healthcare Placement - Spread Should Narrow as Inclusion Draws Closer, and
Celltrion+Celltrion Healthcare Placement- Discount Looks Enticing but the Deal Appears Opportunistic
In this note, we will run the deal through our ECM framework and talk about the recent updates.
Celltrion Pharm Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals. The Company's products include hepatotonics, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs, circularly system drugs, digestives and stomachic drugs, hormone disease drugs, antibiotics, nutrients, tonics, and other drugs. It also provides ethical drugs and over-the-counter (OTC) drugs. The Company distributes its products within domestic market and to overseas markets, including Philippines, Kazakhstan, Cambodia and other Southeast Asia countries.
Aequitas Research is a leading ECM research firm with a focus on IPOs and placements/follow-on offerings across the Asia Pacific with deal size of over USD100m.
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.